⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677684 | 1.00 | — | — | |
| SCHEMBL1987637 | 0.71 | — | — | |
| SCHEMBL1987636 | 0.71 | — | — | |
| SCHEMBL2701677 | 0.69 | — | — | |
| SCHEMBL5957000 | 0.69 | — | — | |
| SCHEMBL1117829 | 0.65 | — | — | |
| SCHEMBL420901 | 0.65 | — | — | |
| SCHEMBL420900 | 0.65 | — | — | |
| SCHEMBL709401 | 0.63 | — | — | |
| SCHEMBL709402 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523277-B1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE OVERSEAS SARL (LU) | 2021-06-30 | — | — | EP | disclosed |
| EP-3523293-B1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | ABBVIE OVERSEAS SARL (LU) | 2021-06-16 | — | — | EP | disclosed |
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-10-17 | — | — | US | disclosed |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-09-03 | — | — | US | disclosed |
| EP-3523293-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| EP-3523277-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3052096-A1 | INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| CN-103497184-A | Pyrrolo-and thiazolo-pyridine compounds as HIF modulators | FIBROGEN INC | 2014-01-08 | — | — | CN | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| CN-101460497-A | Pyrrolopyridine and thiazolopyridine compounds as HIF modulators | FIBROGEN INC (US) | 2009-06-17 | — | — | CN | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |